Ferrer restructures its senior management in Spain. The Catalan pharmaceutical laboratory has named its general manager in the country, Ricardo Castrillo, as head of sales on a global scale, as confirmed by Ferrer to PlantaDoce.
The new position that Castrillo will occupy supposes the vacancy of the general direction of Ferrer in Spain. For now, the company has no substitute, the company explains. Castrillo will be in charge of the commercial work of a group that has a direct international presence in Portugal, Germany, Benelux, Austria, Kazakhstan, the United States, Mexico, Costa Rica, Peru and Chile.
Castrillo came to Ferrer from Chiesi in 2018. The director has more than twenty years of experience in the sector farm. With a degree in Pharmacy from the University of Barcelona (UB) and an MBA from Esade, Castrillo is specialized in marketing, having completed several national and international programs at different business schools.
Ferrer has a direct presence in countries such as Germany, Portugal, Mexico or the United States
Castrillo began his professional career in the pharmaceutical industry at the company Ipsen Pharma, where he held the position of business director. Before joining Ferrer, he was director of the business units of especially which and rare diseases and consumer health en I asked.
In the international arena, his corporate responsibilities in the area of oncology and endocrinology at Ipsen stand out. and his participation as a member of Chiesi’s digital innovation corporate committee.
In 2020, Ferrer achieved a turnover of 555 million euros, which meant an 11% reduction in revenue compared to 2019, according to the latest available results. This decline is largely due to the sale of HealthTech BioActivies, a business specializing in the production of active ingredients, and Diater, a biotechnology company that develops immunotherapy products for allergies. The net result was six million euros44% less.
The company closed 2020 with a turnover of 555 million euros
Ferrer’s gross operating profit (ebitda) in 2020 was 68 million euros, compared to 63 million euros the previous year. Also, bank debt was 110 million euros, compared to 144 million euros twelve months ago.
Ferrer’s latest milestone is the agreement he signed two weeks ago with United Therapeutics for the distribution in Europe of Tyvaso (treprostinil)a pharmaceutical product that combines drug and device to treat pulmonary hypertension.
With this agreement, Ferrer is appointed exclusive distributor and marketer worldwide, with the exception of the United States, Canada, Japan, China and Israel. Pulmonary hypertension is a disease considered rare, serious and progressive without an approved treatment in Europe.
By signing, Ferrer made an initial payment to United Therapeutics, the amount of which was not disclosed. The US company will also receive a transfer price and a share of the proceeds from future sales. The world market for this type of disease is valued at more than $6 billion.
